Literature DB >> 18848843

Regulation of enteric functions by adenosine: pathophysiological and pharmacological implications.

Luca Antonioli1, Matteo Fornai, Rocchina Colucci, Narcisa Ghisu, Marco Tuccori, Mario Del Tacca, Corrado Blandizzi.   

Abstract

The wide distribution of ATP and adenosine receptors as well as enzymes for purine metabolism in different gut regions suggests a complex role for these mediators in the regulation of gastrointestinal functions. Studies in rodents have shown a significant involvement of adenosine in the control of intestinal secretion, motility and sensation, via activation of A1, A2A, A2B or A3 purinergic receptors, as well as the participation of ATP in the regulation of enteric functions, through the recruitment of P2X and P2Y receptors. Increasing interest is being focused on the involvement of ATP and adenosine in the pathophysiology of intestinal disorders, with particular regard for inflammatory bowel diseases (IBDs), intestinal ischemia, post-operative ileus and related dysfunctions, such as gut dysmotility, diarrhoea and abdominal discomfort/pain. Current knowledge suggests that adenosine contributes to the modulation of enteric immune and inflammatory responses, leading to anti-inflammatory actions. There is evidence supporting a role of adenosine in the alterations of enteric motor and secretory activity associated with bowel inflammation. In particular, several studies have highlighted the importance of adenosine in diarrhoea, since this nucleoside participates actively in the cross-talk between immune and epithelial cells in the presence of diarrhoeogenic stimuli. In addition, adenosine exerts complex regulatory actions on pain transmission at peripheral and spinal sites. The present review illustrates current information on the role played by adenosine in the regulation of enteric functions, under normal or pathological conditions, and discusses pharmacological interventions on adenosine pathways as novel therapeutic options for the management of gut disorders and related abdominal symptoms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18848843     DOI: 10.1016/j.pharmthera.2008.08.010

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  46 in total

1.  Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast®) in rat small intestinal preparations.

Authors:  Sebastian Michael; Heba Abdel-Aziz; Dieter Weiser; Christa E Müller; Olaf Kelber; Karen Nieber
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-12-10       Impact factor: 3.000

2.  Emerging adenosine receptor agonists: an update.

Authors:  Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Expert Opin Emerg Drugs       Date:  2011-12-07       Impact factor: 4.191

Review 3.  Modifying radiation damage.

Authors:  Kwanghee Kim; William H McBride
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

4.  Enteric nervous system in the small intestine: pathophysiology and clinical implications.

Authors:  Behtash Ghazi Nezami; Shanthi Srinivasan
Journal:  Curr Gastroenterol Rep       Date:  2010-10

5.  Differential expression of genes related to purinergic signaling in smooth muscle cells, PDGFRα-positive cells, and interstitial cells of Cajal in the murine colon.

Authors:  L E Peri; K M Sanders; V N Mutafova-Yambolieva
Journal:  Neurogastroenterol Motil       Date:  2013-06-30       Impact factor: 3.598

6.  Neuropharmacology of purinergic receptors in human submucous plexus: Involvement of P2X₁, P2X₂, P2X₃ channels, P2Y and A₃ metabotropic receptors in neurotransmission.

Authors:  A Liñán-Rico; J E Wunderlich; J T Enneking; D R Tso; I Grants; K C Williams; A Otey; K Michel; M Schemann; B Needleman; A Harzman; F L Christofi
Journal:  Neuropharmacology       Date:  2015-02-24       Impact factor: 5.250

7.  Adenosine and its receptors as therapeutic targets: An overview.

Authors:  Sakshi Sachdeva; Monika Gupta
Journal:  Saudi Pharm J       Date:  2012-06-23       Impact factor: 4.330

Review 8.  Potential for developing purinergic drugs for gastrointestinal diseases.

Authors:  Fernando Ochoa-Cortes; Andromeda Liñán-Rico; Kenneth A Jacobson; Fievos L Christofi
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

9.  Role of the A(2B) receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rats.

Authors:  L Antonioli; M Fornai; O Awwad; G Giustarini; C Pellegrini; M Tuccori; V Caputi; M Qesari; I Castagliuolo; P Brun; M C Giron; C Scarpignato; C Blandizzi; R Colucci
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

10.  Anti-inflammatory effect of a novel locally acting A2A receptor agonist in a rat model of oxazolone-induced colitis.

Authors:  L Antonioli; A El-Tayeb; C Pellegrini; M Fornai; O Awwad; G Giustarini; G Natale; L Ryskalin; Z H Németh; C E Müller; C Blandizzi; R Colucci
Journal:  Purinergic Signal       Date:  2017-11-08       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.